- Home
- ATOS
as 11-21-2024 4:00pm EST
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 174.8M | IPO Year: | 2012 |
| Target Price: | $6.75 | AVG Volume (30 days): | 738.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $2.31 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Atossa Therapeutics Inc. News
ATOS Breaking Stock News: Dive into ATOS Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 hours ago
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
GlobeNewswire
2 days ago
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Zacks
3 days ago
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
GlobeNewswire
10 days ago
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
17 days ago
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
GlobeNewswire
18 days ago
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
GlobeNewswire
22 days ago
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
Zacks
25 days ago
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Compare ATOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATOS Atossa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.